The abstract is read at the publisher; the summary is JClub's.
KHSRP is the top vulnerability in therapy-persistent acute myeloid leukemia, and its depletion sensitizes AML to treatment and substantially prolongs survival in treated AML-bearing mice.
- Why it matters: Residual AML cells that persist after therapy have distinct biology, but specific, actionable vulnerabilities in this population are not well defined.
- What they did: Genome-wide CRISPR interference screens in leukemia cells treated with multiple agents identified KHSRP; in vivo, residual disease after venetoclax/azacitidine showed downregulation of SLC23A1, which KHSRP depletion restored by blocking ZC3H4-mediated nuclear mRNA degradation.
- The result: Restoring SLC23A1 via KHSRP depletion enhanced synergistic cytotoxicity of vitamin C and uric acid in therapy-persistent leukemia, and TET2 re-expression overrode this chemosensitizing effect in TET2-mutant leukemia.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.